[A20-35] Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 01.10.2020
Project no.:
A20-35
Commission:
Commission awarded on 31.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies
In case of 2 prior regimens: hint of greater harm due to side effects. In case of more than 2 prior therapies, due to major survival advantage and analogue side effects: hint of minor added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-85 | Trifluridine/tipiracil (gastric cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-54 | Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-72 | Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A20-35 | Commission completed |
Federal Joint Committee (G-BA)
2020-10-01 A G-BA decision was published.